Ergoteles’s Aethlon Medical AEMD Stock Holding History

Ergoteles’s Portfolio AEMD Stock Details AEMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-63	Closed	-$13.9K	–	1199
2022 Q4	$13.9K	Buy	+63	New	+$23K	﹤0.01%	1359

Other funds holding AEMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AFGAS

Allegiance Financial Group Advisory Services Vienna, Virginia $503M AUM 22.39% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ergoteles's AEMD Position: Q1 2023 in Review

Ergoteles sold out of Aethlon Medical (AEMD) in Q1 2023, closing a stake of 63 shares — an estimated $13.9K sold.

Ergoteles first reported a position in AEMD in Q4 2022 and held it in 1 quarter. The position peaked at $13.9K in Q4 2022. 23 funds tracked by Wall St. Rank hold AEMD as of Q1 2023.

Ergoteles reported no remaining Aethlon Medical position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 63 Aethlon Medical shares in Q1 2023, an estimated $13.9K.
Ergoteles first reported a position in Aethlon Medical in Q4 2022 and held it in 1 quarter.
Ergoteles's Aethlon Medical position peaked at $13.9K in Q4 2022.
23 funds tracked by Wall St. Rank held Aethlon Medical as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.